Artificial Intelligence in Pharmacology Research

[1] Diksha Shinde, [2] Dattatraya Kature, [2]Vikesh Kukade

[1] Institute of Pharmaceutical Sciences and Research, Swami Chincholi, Daund, Pune

[2] Delonix Society's Baramati College of Pharmacy. Barhanpur, Baramati, Pune

Received : 5 December 2023 Accepted : 20 December 2023

Abstract

AI has become an integral part of the entire spectrum of pharmacology research and clinical practice, extending from early drug discovery to real-world data mining. The utilization of AI models varies, encompassing unsupervised clustering for the identification of potential drug compounds or suitable patient populations, as well as supervised machine learning approaches to enhance therapeutic drug monitoring. Moreover, natural language processing is gaining prominence for mining electronic health records to extract real-world insights.

AI has proven its efficacy in drug discovery and target identification for several years. More recently, emerging AI models aid in characterizing patient populations and predicting individual drug responses, thereby spanning the entire pipeline from drug discovery to personalized medicine. In 2020, there was extensive discussion about the use of AI in clinical pharmacology, and many of those applications remain in use and relevant. Nevertheless, numerous new developments have transpired since then. This discussion will delve into the present utilization of diverse AI and ML approaches within the realm of pharmacology. Recently, artificial intelligence (AI) has gained recognition for its application across various domains of pharmaceutical science, particularly in pharmacological research. It plays a pivotal role in analyzing preclinical (lab animals) and clinical (in humans) trial data. Moreover, AI proves indispensable in multiple facets, including drug development and manufacturing, extensive data analysis for disease detection, personalized treatment, clinical trial research, radiation, surgical robotics, smart electronic health records, and the prediction of epidemic outbreaks.

Introduction :

Artificial intelligence, a subfield of computer science, demonstrates the capability to analyze complex medical data. Its proficiency in identifying significant relationships within data collections can be applied across various clinical scenarios, including diagnosis, therapy, and outcome prediction. The field of science and technology known as artificial intelligence (AI) is nascent. At all societal levels, from individuals to social organizations, corporations, and governments, it already has an impact on a variety of human activities. In almost every industrial, economic, and societal sector, including information technologies, manufacturing, space, remote sensing, security and defense,

Author Correspondence
Dr. Aishwarya Dhole
Delonix Society's Baramati College of Pharmacy.
Barhanpur, Baramati, Pune
Email : dattakaturebcop@gmail.com

transportation and vehicles, and, since the turn of the century, medicine and health care, AI has been rapidly expanding. [1,2]

Tools of ever-greater sophistication have been created throughout many ages to benefit the human race. In many ways, digital computers are just another tool. They are capable of performing the same types of numerical and symbolic manipulations as a regular person, but more quickly and accurately. The question of whether we can create a computer (or computer programme) that can think is more intriguing. [3] As Penrose (1989) has noted, the majority of us are fairly content with devices that allow us to perform physical tasks more swiftly or effortlessly, such as driving down a motorway or digging. [4] We are also content to employ tools that let us perform physical tasks that would be otherwise impossible, like flying. However, the concept of a machine that can think for us is a significant advancement in our aspirations and one that raises numerous ethical and philosophical issues. The goal of artificial intelligence (AI) research is to create such a computer and to better understand intelligence. The science behind computer systems that replicate human thinking processes is known as artificial intelligence. Building a machine that can duplicate or outperform human mental talents, including thinking, understanding, imagination, perception, recognition, creativity, and emotions, would be the field's pinnacle achievement. Even while we are still far from accomplishing this, we have had some very significant victories. A family of incredibly practical computing tools has been created as a result of artificial intelligence research, which is maybe even more significant than these small triumphs.

These tools have made it possible to solve many issues that were previously thought to be insurmountable and to solve many other problems more successfully. From a practical standpoint, this alone makes them intriguing and valuable. [6]

The following major categories can be used to generally classify AI tools:

Artificial intelligence (CI), which is implicit modeling with numerical approaches; knowledge-based systems (KBSs), which are explicit models utilizing words and symbols. Techniques including rule-based, model-based, frame-based, and case-based reasoning fall within the first category. The knowledge can be read and comprehended by humans since it is explicitly modeled in words and symbols. Although symbolic techniques have unquestionably been successful in their own fields, they are inherently restricted in that they can only deal with circumstances that have been modeled explicitly. Despite the fact that some methods permit the model to grow Symbolic representations are typically bad at coping with the unfamiliar.[7]



Figure 1- Categories of Intelligant system software

According to John McCarty, the father of artificial intelligence, artificial intelligence is the study of utilizing computer programs to make machines intelligent. The AI claims that "Today's Science is Tomorrow's Technology," which indicates that all humans must assert their presence while utilizing technical knowledge in order to survive. [8]

When do we refer to AI?

The term artificial intelligence (AI) is used when a human-made computer simulates some functions so that many human minds come together to solve a problem and learn something.



Figure 2- Sectors in Artificial Intelligence



Figure 3- Application of AI in various branches of Science

The term "Medical Technology" is commonly employed to encompass a range of tools aimed at aiding medical professionals in early diagnosis, complication prevention, treatment optimization, providing less invasive options, and reducing hospital stays for both individual patients and society at large. Before the era of smartphones, wearables, sensors, and communication systems, medical technologies were predominantly referred to as traditional medical devices, including prosthetics, stents, and implants. [9] Yet, the evolution of smartphones, wearables, sensors, and communication systems has transformed medicine by introducing exceptionally compact artificial intelligence (AI) powered tools. These programs, often in remarkably small sizes, have sparked a revolution in medical technology. Artificial intelligence (AI), typically associated with computer science, is recognized for its ability to tackle complex challenges across various fields characterized by extensive data but limited theoretical frameworks. [2]

The broader community has welcomed intelligent medical technologies, particularly those powered by AI, as they facilitate the 4P model of medicine—Predictive, Preventive, Personalized, and Participatory. This has, in turn, empowered patient autonomy in ways that were previously unattainable. [3] For example, smartphones are increasingly being used to fill out and distribute electronic personal health records [4], monitor vital functions with biosensors [5], and support remote patient monitoring. The rise of augmented medicine, or the application of modern medical technology to enhance different areas of clinical practice, is made possible by the development of intelligent medical technologies. The Food and Drug Administration (FDA) has approved several AI-based algorithms in the last ten years; as a result, they could be used. Several other digital tools, such as surgical navigation systems for computer-assisted surgery [7], virtuality-reality continuum tools for surgery, pain management, and mental diseases, as well as AI-based technologies, enable augmented medicine. [10] While augmented medicine has gained favor with patients, it encounters resistance from medical professionals, particularly doctors. To elucidate this phenomenon, four commonly cited reasons should be addressed. Firstly, a notable lack of comprehensive and continuous training in this field leads to unpreparedness for the potential of digital medicine. [11] Secondly, the initial digitization of healthcare processes markedly differed from the envisioned benefits of augmented medicine, as it brought about a substantial surge in administrative burdens, primarily linked to electronic health records. [12], This is now acknowledged as one of the primary contributors to physician burnout. Thirdly, despite the prevalent and widely accepted belief in the literature that AI will eventually complement physician intelligence. [13, 14], there is growing concern that doctors could be replaced by machines [15]. Fourthly, doctors utilizing AI are vulnerable to potential legal consequences due to the absence of a global legal framework establishing liability for the acceptance or rejection of algorithmic recommendations.

The core of medical practice has traditionally involved gathering extensive data about a patient's health or disease and making decisions based on that information. Physicians have depended on their experience, judgment, and problem-solving skills, often using basic tools and limited resources. However, with the advent of the digital health cultural transformation, disruptive technologies have begun to provide advanced methods not only to medical professionals but also to their patients. [16]

The core of medical practice has always been gathering as much information as possible about the patient's health or illness and making judgments based on that information. Using crude

instruments and scant resources, doctors have had to rely on their knowledge, judgment, and problem-solving abilities.

Disruptive technologies have begun to make cutting-edge techniques accessible to patients as well as medical professionals thanks to the cultural shift known as digital health. Wearable sensors, biotechnology, and artificial intelligence (AI) are a few examples of the technologies that are increasingly pointing in three main directions. They have been (1) turning the patient into the focal center of care, (2) generating enormous amounts of data that demand sophisticated analytics, and (3) laying the groundwork for precision medicine. Medicine has evolved toward prevention, personalisation, and precision rather than developing therapies for populations and making the same medical decisions based on a few similar physical traits among patients.AI is the primary technology in this shift and cultural transformation that can help people take advantage of this potential in their daily lives.

We began to question if human doctors might eventually be replaced by AI tools in the healthcare industry as a result of recent advancements in AI technology. Practically speaking, AI tools may not be able to completely replace human doctors, but they can help them get better outcomes and more accuracy in the medical setting. The availability of healthcare data is a key factor supporting the development of AI solutions in the medical industry.

Artificial intelligence comprises a variety of technologies, extending beyond a single entity. Among these technologies, machine learning is commonly employed in healthcare. Machine learning involves training models with existing data, allowing them to recognize and interpret new input based on pre-existing knowledge. Machine learning stands out as one of the most widely utilized types of artificial intelligence. [17]

Precision medicine is where machine learning is utilized in healthcare the most frequently. Precision medicine makes predictions about which treatment plans will be effective for a certain patient based on patient data from the past. [1] In order to determine from prior learning, the model must be trained using datasets; this process is known as supervised learning. Figure 1 illustrates some applications of AI in pharmacy and healthcare. [17]

Applications of AI in ADMET predictions :

As AI tools have become more prevalent, in silico assessments of absorption, distribution, metabolism, excretion, and tolerated toxicity (ADMET) have advanced significantly. As a result, more accurate models have been created. Methods like DNNs, ANNs, RFs, and SVMs, as well as k-NN, have paved the way in this sector with good performance, but there are still a number of variables to take into account, such encoding functions, the volume and calibre of input data, and many more. According to various research, intestinal medication absorption has one of the highest influences on bioavailability and is accurate with an acceptable range. On a dataset with 104 and 26 molecules (the training and test sets, respectively), a novel hierarchical SVM scheme was created to predict the colon cancer cell layer (Caco-2); the model had outstanding qualitative performance and revealed great accuracy. Prior to that, DNN architecture. However, a number of aspects need be taken into account, such as encoding functions, the quantity and quality of input data. Techniques like DNNs, ANNs, RFs and SVMs, and k-NN have opened a wide avenue in this subject with good results. One of the factors that most affects bioavailability is intestinal medication absorption, which various studies have proven for accuracy with a tolerable range. [18] A novel hierarchical SVM strategy was created to predict the Caco-2 cell layer of colon

cancer using datasets including 104 and 26 molecules, respectively (training and test set). The model had outstanding qualitative performance and revealed great accuracy. Previously, a DNN architecture was suggested employing 209 molecular descriptors and shown good discriminant power for the prediction of cellular permeability in compound-derived Caco-2 cell lines. . Four approaches were integrated in a bigger dataset (1272 chemicals) to predict permeability, including boosting, partial least-squares PLS, SVM, and MLR. The boosting model was the most effective and had the highest Q2, RMSE, CV, and R2 values. A important pharmacokinetic factor that affects the medication volume distribution is plasma protein binding (PPB). Predictive models have been constructed using heterogeneous data in silico due to the time-consuming and expensive nature of conventional tests. When predicting the PPB values of cyclic peptides using two algorithms (forward beam search and enumerating lasso solutions), the ELS was more reliable in predicting a wide range of molecules with strong generalisation ability. The authors of a study presented six models (SVM, ANN, k-NN, PLS, Probabilistic neural network, Linear discriminant analysis) in a dataset of 736 compounds. While all methods were highly effective at binary classification and PPB prediction, SVM showed the best accuracy, sensitivity, specificity, precision, and F1 score. Prediction models have also been developed in order to learn more about other natural barriers that affect drug distribution, such as the blood-brain barrier (BBB). [19] The accuracy and specificity scores of the proposed DL-based RNN to predict chemical penetration to the CNS were 96.53% and 98.08%, respectively; the dataset included compounds encoded in SMILES (1803 BBB+ and 547 BBB substances). To predict the BBB ability of marine-derived kinase inhibitors, multiple binary classifiers and logistic regression were developed (18 models). The accuracy of RF, gradient boosting, and logistic regression was the top-performing model. In a nutshell, the broad range of applications for AI methods can lighten the workload of several clinical studies for medication distribution research. There have been numerous investigations of AI in the subject of metabolism predictions to look into the locations of metabolism, the isoforms responsible for the process, and metabolic pharmacokinetics and pharmacodynamics (drug-drug interactions). To predict protein subcellular localization from the dataset retrieved from the UniProt database, DeepLoc (DNN-based model) has been provided; in the independent test set, the accuracy obtained was highest (compared to other methods: LocTree2, MultiLoc2, MultiLoc2, YLoc, CELLO, iLocEuk, WoLF PSORT).Use of the Laplacian-modified naive Bayesian technique to classify the effectiveness of 4500 substances as inhibitors of five CYP isoforms Moreover, five network-based label space division (NLSD)-based approaches, twin SVMs, and multilabel kNNs were used to explore the substrate selectivity of the CYP450 enzyme using a dataset of 484 chemicals and 1299 compound/isoform pairs; reached NLSD-XGB.the best results using the HO and CV approaches. A study that examined the interaction between CYP inhibitors and their ability to inhibit CYP provided a Super CYPsPred web server based on the RF algorithm that was focused on five CYP isoenzymes and contained 17 143 compounds. To discover pharmacological interactions with G-protein coupled receptors (GPCRs), a new sequencing technique based on distance-weighted kNN has been proposed.A study used the BIOiSIM platform's integrated coarse-tuning and fine-tuning algorithms to predict drug exposure (AUC, Cmax, and Tmax).Recently, there has been an increase in the creation of AI-based excretion predictors to study the paths for clearance. CPathPred, a recently developed SVM-based predictor on a dataset of 141 authorised

pharmaceuticals, has boosted the ease of molecular descriptors and major clearance pathways.Total plasma clearance (Cltot) of 1114 compounds was determined by StarDrop using eight different techniques (PLS, radial basis function fitting (RBF), RF, Gaussian process models (GP) with two-dimensional search for parameters (GP2DS), fixed hyperparameters (GPFixed), and hyperparameters obtained by forwarding variable selection. the use of ML techniques enhances the screening paradigm in the first stages of medication R&D with numerou(GPFVS) and rescaled procedure (GPRFVS), as well as by conjugate gradient optimisation (GPOPT));These in silico models showed superior predictability to in-vitro tests. As a result, the use of ML techniques enhances the screening paradigm in the first stages of medication R&D with numerous advantages. [20]

Decoding empaglifozin's molecular mechanism of action in heart failure with preserved ejection fraction using artifcial intelligence:

Sodium-glucose co-transporter 2 inhibitors are being studied for the treatment of heart failure with preserved ejection fraction (HFpEF), however it is not understood how they work exactly. Here, our goal was to apply artificial intelligence (AI) to describe the molecular basis of empaglifozin's activity in HFpEF. We retrieved data on empaglifozin target information and biofags, together with information on HFpEF pathophysiological themes and differentially expressed genes/proteins, from specialized publically accessible sources. [21]

Deep learning AI and artificial neural networks were utilized to simulate the molecular effects of empaglifozin in HFpEF. According to the model, empagliflozin could undo 59% of the protein changes discovered in HFpEF. Inhibition of NHE1 (Na+/H+ exchanger 1) appeared to be the primary mechanism by which empaglifozin's effects in HFpEF were mediated, with SGLT2 appearing to play a less significant role. The chemical mechanism of action explanation was 94% accurate. Empaglifozin's pharmacological activity predominantly affected cardiomyocyte oxidative stress regulation and significantly influenced heart concentric hypertrophy, systemic inflammation, myocardial extracellular matrix remodeling, and cardiomyocyte stiffness. These findings suggest empaglifozin's possible application in HFpEF. [22]

Nearly half of all cases of heart failure (HF) are currently heart failure with preserved ejection fraction (HFpEF), and no evidence-based treatment has been shown to enhance outcomes. The current treatment for heart failure with reduced ejection fraction (HEpEF) is based on modulating neurohormonal activation, which involves limiting excessive renin-angiotensin-aldosterone and sympathetic nervous system activation and boosting the body's endogenous natriuretic peptide defenses. patient's lowering plasma concentrations of NOS2, the NLPR3 infammasome, and TGF-1 over the course of a year of empagliflozin medication were used to validate these in silico results in vivo. [23] We discovered via AI modeling that the primary effect of empagliflozin in the therapy of HFpEF is exerted via NHE1 and is focused on the control of cardiomyocyte oxidative stress.

These findings suggest empaglifozin's possible application in HFpEF.Nearly half of all cases of heart failure (HF) are currently heart failure with preserved ejection fraction (HFpEF), and no evidence-based treatment has been shown to enhance outcomes. The current treatment for heart failure with reduced ejection fraction (HFrEF) is based on modulating neurohormonal activation, which involves limiting excessive renin-angiotensin-aldosterone and sympathetic nervous system activation and boosting the body's endogenous natriuretic peptide defenses. However,

in numerous important HFpEF1-3 experiments, such tactics did not fare as well.A novel family of medications called sodium-glucose co-transporter 2 inhibitors (SGLT2i) is being studied for use in HF. Two expedited landmark clinical trials, the DAPA-HF with dapaglifozin4 and the Emperor-Reduced with empaglifozin5, have produced better than expected clinical benefits in HFrEF, with and without diabetes. Both dapaglifozin and empaglifozin are now undergoing pivotal clinical trials in HEpEF.The proximal renal tubule's SGLT2 receptor is blocked as part of SGLT2i's mechanism of action. 90% of glucose reabsorption into the bloodstream is carried out by SGLT2 receptors, and their blockage causes glycosuria and lower glycemic levels [6,7]. But SGLT2i-induced glycaemic control by itself seems to be effective.

Cardiovascular disease and type 2 diabetes together increase the chance of death. Type 2 diabetes is a major risk factor for cardiovascular disease. [24] There is insufficient proof that reducing blood sugar lowers the incidence of cardiovascular disease and death, although long-term follow-up studies may reveal a small cardiovascular benefit. [25] Additionally, there is worry that aggressive glucose reduction or the use of particular glucose-reducing medications may lead to unfavorable cardiovascular outcomes. [8] The advantages of glucose-lowering medications for cardiovascular safety must therefore be established.

Because sodium-glucose cotransporter 2 inhibitors increase urine glucose excretion by reducing renal glucose reabsorption, they lower the rates of hyperglycemia in people with type 2 diabetes.10 A medication for type 2 diabetes called empagliflozin is a specific inhibitor of sodium glucose cotransporter 211.12 The medication is claimed to lower glycated hemoglobin levels in individuals with type 2 diabetes, including those with stage 2 or 3a chronic renal disease, whether given as either a monotherapy or as an add-on therapy.13-20 Empagliflozin is also linked to decreased blood pressure and weight loss without an increase in heart rate.13-20 13-19 Both levels of low-density lipoprotein (LDL)14 and high-density lipoprotein (HDL) cholesterol have been shown to rise in response to empagliflozin.13-16 Urinary tract infection and vaginal infection are two of empagliflozin's most frequent adverse reactions. Additionally, empagliflozin is beneficial for indices of vascular resistance and arterial stiffness, as well as visceral obesity, albuminuria, and plasma urate. [26]

Mechanism of Action Elucidation :

Predictions based on artificial neural network (ANN) analysis indicate that the efficacy of empagliflozin in HFpEF primarily stems from the inhibition of NHE1 (Na+/H+ exchanger 1), with comparatively lesser involvement of other targets like SGLT2 and NHE3 (refer to Table 1). It's crucial to note that NHE1 is the sole target protein expressed in both cardiomyocytes and vascular cells for empagliflozin. The AI mathematical models further analyzed the molecular interactions, highlighting NHE1 inhibition as the primary mechanism for empagliflozin's therapeutic effects in HFpEF, while SGLT2 and NHE3 played subsidiary roles (see Table 1). With a noteworthy mean accuracy of 94%, the analysis identified the most probable mechanism of action from a pool of 250 physiologically plausible possibilities. A number of significant conclusions can be drawn from Fig. 4.



Figure 2. Graphical representation of the identified mechanism of action of empagliflozin in HFpEF. These paths were predicted by mathematical modelling, and biologically contextualized. Green lines indicate activations; red lines indicate inhibition; and blue lines indicate either activation or inhibition (cell-dependent effect). Broken lines show nodes that contain more than one protein, all of which participate in the mechanism of action in the same way.

Figure 4- Graphical representation of the identified MOA of empagliflozin in HFpEF

First off, it seems that one unique effect of empagliflozin is the modulation of oxidative stress mechanisms (an upstream event in the development of HFpEF), via the cardiomyocyte-expressed target NHE1 through a variety of effectors, including AKTs (RAC-alpha/beta/gamma serine/threonine-protein kinases), nuclear factors of activated T-cells signaling (NFATs), and nitric oxide synthase (NOS2). Second, it is obvious that the mechanism of action of empagliflozin has a significant negative impact on systemic inflammation. Tumor necrosis factor- (TNF-), interleukin-1 (IL-1), intercellular adhesion molecule-1 (ICAM1), and the NACHT, LRR, and PYD domains-containing protein 3 (NLRP3) inflammasome were among the proteins altered by this drug in our simulation, which decreased inflammation. Last but not least, we saw significant alteration of cardio-myocyte stiffness, myocardial extracellular matrix remodeling, and heart-concentric hypertrophy processes downstream of empagliflozin-mediated NHE1 inhibition. Vascular endothelial growth factor A (VEGFA), NF-B-induced collagen alpha-1 chain (CO1A1), transforming growth factor (TGF)-1, NFATs, and interleukin-10 (IL-10) are the mediators of these empagliflozin-inhibited myocardial changes. These events were identified in the models as the more indirect effects of NHE1 inhibition on oxidative stress. [27]

Artificial Intellience Modelling :

Modes - Artificial neural networks (ANNs) operate under supervision, employing algorithms to discern connections between proteins (such as drug targets) and various clinical components within a network. This involves deducing the likelihood of a specific relationship existing between two or more sets of proteins. The system endeavors to determine the most efficient path between two assessed protein sets, consequently producing a ranked list of proteins based on their association with the specified pathophysiology. In this study, ANNs were employed for the subsequent analyses:

(1) Comparison of individual targets of empagliflozin in HFpEF (as a whole) and in each pathophysiological motif; synthetic neural networks (ANNs). ANNs are managed. Methods that determine connections between proteins (such as drug targets) and network clinical components47, by inferring Calculate the

likelihood that a specific association between two or more protein sets exists. It system endeavors to Find the distance that separates two protein sets that have been analyzed in order to create a list of proteins according to their relationship to the defined pathology. ANNs were employed in this study for the following tasks:

(1) Analyses comparison of empagliflozin's specific goals in HFpEF (generally) and in each physiopathological theme

(2) Identifying the biomarkers of empagliflozin in HFpEF; and

(3) comparing the efficacy of empagliflozin to other medications that have been studied in HFpEF (ACEI, ARBs, beta-blockers, MRA, ARNI), including analyses of each medication's relationship to the disease. Models in mathematics. In order to replicate the behavior of HFpEF and the projected effects of empagliflozin, in terms of changes in protein activity within the human protein network, we lastly created mathematical models that combined all relevant biological and pharmacological knowledge. Briefly, the actions listed below were done.

First, input models were produced using data on empagliflozin, HfpEF, and the protein/gene connections found in open-access databases. These models were used to assess how the signaling cascade was affected by the inhibition or activation of one or more nodes within the protein network. Second, output models were created using experimental RNA sequence data (upregulated or downregulated genes/proteins) to provide detailed and precise information about the disorders to the mathematical models. The complex protein network interaction structure and network activation signal flow were modeled using cutting-edge AI technology. [28] These included stochastic techniques like Simulated Annealing and Monte Carlo911, genetic algorithms, ANNs, dimensionality reduction techniques, and statistical pattern recognition technologies. Two distinct types of analysis were carried out by use of advanced AI:

(1) Estimating the therapeutic potency of empagliflozin in HFpEF (details are available in the online supplemental material.

(2) Creating an in-depth explanation of the molecular mechanisms behind empaglifozin's mechanism of action. To guarantee portrayal of the proteins most affected by empaglifozin in HfpEF, the graphical representation was watched carefully. This approach ensured detailed observation of the drug's downstream effects on the various HfpEF mechanisms.

The intensity of the reaction:

The term "intensity" of the response is used to quantify and assess the impact of a certain mechanism of action. The amount of protein effectors or motivations (#Ef) achieving the anticipated signal to ameliorate a disease is defined as the intensity in this research. We determined the number of effectors reaching the expected signal (#Ef) by assuming yi as the value attained by a protein effector "i," vi as its expected effector sign (active or inactive), and n as the overall number of effectors described for a phenotypic (HFpEF). The effects of a medication (empagliflozin) are anticipated to reverse a disease's phenotype. As a result, a medication should activate the inactive protein effectors of a pathogen while inactivating the active ones. However, the number of pathology-related effectors achieving an output signal with the polarity opposite to that defined in the condition characterization is what is being counted. Using Dirac's d (d(0)=1, otherwise 0, zero).

Artificial Intelligene In Clinical Research and Trials :

Living in the modern lifespan can result in the daily production of vast amounts of medical

data. The use of artificial intelligence (AI) in pharmaceutical science, particularly pharmacological research, has grown in recent years. It helps in the analysis of preclinical (laboratory animals) and clinical (in humans) trial data. AI has been used in the evaluation of biomarkers and diseases. AI provides the best approach for a better healthcare system. AI and ML are helping to manage the best healthcare options for physicians, consumers, insurers, and regulators.

The academic community, research and development (R&D) organizations, industrial units, clinical settings, and community pharmacies are just a few of the sources from which data is collected. A better choice to coordinate the vast amounts of healthcare data and enhance the healthcare system and therapies is provided by AI and ML. [29]

The pharmaceutical sciences are greatly impacted by AI/ML. When compared to traditional technologies, the use of numerous analytical techniques including magnetic resonance imaging (MRI), X-ray, electrocardiogram (ECG), and histopathological imaging yields more accurate results with the aid of variable sensor and data acquisition systems.

In the process of inventing drugs, synthesizing chemicals, and analyzing biological test results, it has been hoped that creative collaboration between the mind and machine will lead to better decisions. The general process of developing an AI model for drug discovery involves four steps: first, defining the problem, whether it be specific or general, second, selecting an appropriate AI algorithm, and third, preparing input data that are satisfactory in terms of quality and quantity, representation characteristic, and fitting proportion. Finally, the model training and evaluation. [30]

The pharmaceutical sector has approached excellent platforms of AI technologies for drug repurposing for mixed data sources such as PREDICT, Netlap RLS, and DTINet. The majority of research that has been published so far has used learning algorithms to make precise predictions based on establishing a significant association between the medications, the targets, and the disease.

AI is employed at many levels of preclinical testing and data collection in the drug development process. AI is also utilized to forecast the efficacy, pharmacokinetics, and safety of medicinal molecules. AI is also employed in pharmaceutical sciences for production procedures, combination studies, and drug targeting studies.

Various methods of artificial Intelligence are as follows-

1) MRI, X-ray, ECG
2) NLP
3) LSSVM
4) PSOWNN
5) EPNN
6) GLCM
7) NN/XY-Fusion
8) QSAR
9) GAN, DNDD
10) BBPs, ACPs
11) NMR
12) DNNs, ANNs, RFs, and SVMs, k-NN
13) VigiGrade, VigiRank
14) CMap, GWAS
15) LapRLS

The use of artificial intelligence (AI) for healthcare purposes has constantly increased, and pharmacology has seen a wide range of applications. Modern pharmacology research and clinical practice incorporate AI at every stage, from early drug discovery to in-depth data mining.

By examining the chemical structure and properties, AI may be used to aid in the selection of the compounds that have the best chance of being successful. To begin with, if the target is known, AI can be used to foretell the kinds of

chemical structures that might attach to the target in the intended manner. The chemical makeup of well-known, effective medications or endogenic agents can also be utilized to pinpoint targets and reveal the details of potential pharmacological targets. Last but not least, an understanding of known medicinal molecules, pharmacokinetics (PKs), and pharmacodynamics can be used to anticipate the in vivo properties of a novel compound. [31]

The selection of patients who match the eligibility requirements and are most likely to engage can be improved with the use of AI systems, which can process vast amounts of EHR data. As a result, less time and money are wasted trying to find patients. Second, AI can support trial-related patient monitoring.

Utilizing digital twins, AI can be used to predict a patient's response to medicine in traditional clinical trials and data mining. In virtual clinical trials AI-based decision support tools that can be thought of as medical devices will begin to see use in clinical pharmacology.

References:

1. Ramesh AN, Kambhampati C, Monson JR, Drew PJ. Artificial intelligence in medicine. Annals of the Royal College of Surgeons of England. 2004 Sep;86(5):334.
2. Gómez-González E, Gomez E, Márquez-Rivas J, Guerrero-Claro M, Fernández-Lizaranzu I, Relimpio-López MI, Dorado ME, Mayorga-Buiza MJ, Izquierdo-Ayuso G, Capitán-Morales L. Artificial intelligence in medicine and healthcare: a review and classification of current and near-future applications and their ethical and social Impact. arXiv preprint arXiv:2001.09778. 2020 Jan 22.
3. Punn M, Bhalla N. Classification of wheat grains using machine algorithms. International Journal of Science and Research (IJSR). 2013 Aug;2(8):363-6.
4. Oke SA. A literature review on artificial intelligence. International journal of information and management sciences. 2008 Dec 1;19(4):535-70.
5. Briganti G, Le Moine O. Artificial intelligence in medicine: today and tomorrow. Frontiers in medicine. 2020 Feb 5;7:27.
6. Mesko B. Artificial intelligence will redesign healthcare. Medical Futurist.
7. Manne R, Kantheti SC. Application of artificial intelligence in healthcare: chances and challenges. Current Journal of Applied Science and Technology. 2021 Apr 24;40(6):78-89.
8. Ramesh AN, Kambhampati C, Monson JR, Drew PJ. Artificial intelligence in medicine. Annals of the Royal College of Surgeons of England. 2004 Sep;86(5):334
9. Turing AM. Computing machinery and intelligence (1950). The Essential Turing: the Ideas That Gave Birth to the Computer Age. 2012:433-64.
10. Flaxman AD, Vos T. Machine learning in population health: opportunities and threats. PLoS medicine. 2018 Nov 27;15(11):e1002702.
11. Yin Z, Yao C, Zhang L, Qi S. Application of artificial intelligence in diagnosis and treatment of colorectal cancer: A novel Prospect. Frontiers in Medicine. 2023 Mar 8;10:1128084.
12. Bi WL, Hosny A, Schabath MB, Giger ML, Birkbak NJ, Mehrtash A, Allison T, Arnaout O, Abbosh C, Dunn IF, Mak RH. Artificial intelligence in cancer imaging: clinical challenges and applications. CA: a cancer journal for clinicians. 2019 Mar;69(2):127-57
13. Thakur N, Yoon H, Chong Y. Current trends of artificial intelligence for colorectal cancer pathology image analysis: a systematic review. Cancers. 2020 Jul 13;12(7):1884.
14. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36

cancers in 185 countries. CA: a cancer journal for clinicians. 2021 May;71(3):209-49.

15. Lu Y, Xin D, Wang F. Predictive significance of preoperative systemic immune-inflammation index determination in postoperative liver metastasis of colorectal cancer. OncoTargets and therapy. 2019 Sep 20:7791-9.
16. Joseph DA, Meester RG, Zauber AG,Manninen DL, Winges L, Dong FB, Peaker B, van Ballegooijen M. Colorectal cancer screening: estimated future colonoscopy need and current volume and capacity. Cancer.2016 Aug 15;122(16):2479-86.
17. Bayes-Genis A, Iborra-Egea O, Spitaleri G, Domingo M, Revuelta-López E, Codina P, Cediel G, Santiago-Vacas E, Cserkóová A, Pascual-Figal D, Núñez J. Decoding empagliflozin's molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence. Scientific reports. 2021 Jun 8;11(1):12025.
18. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine. 2015 Nov 26;373(22):2117-28.
19. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A. Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine. 2008 Dec 4;359(23):2456-67.
20. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W. Cardiovascular and renal outcomes with empagliflozin in heart failure. New England Journal of Medicine. 2020 Oct 8;383(15):1413-24.
21. Kosmas CE, Silverio D, Sourlas A, Montan PD, Guzman E. Role of spironolactone in the treatment of heart failure with preserved ejection fraction. Annals of translational medicine. 2018 Dec;6(23).
22. Pitt, B. et al. TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N. Engl. J. Med. 370, 1383–92 (2014).
23. Solomon, S. D. et al. PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with pre-served ejection fraction. N. Engl. J. Med. 381, 1609–1620 (2019).
24. Verma S, McMurray JJ. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018 Oct;61:2108-17.
25. Chirinos JA. Deep phenotyping of systemic arterial hemodynamics in HFpEF (part 2): clinical and therapeutic considerations. Journal of cardiovascular translational research. 2017 Jun;10(3):261-74.
26. Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. European journal of heart failure. 2011 Jan;13(1):18-28.
27. Hoekstra T, Lesman-Leegte I, van Veldhuisen DJ, Sanderman R, Jaarsma T. Quality of life is impaired similarly in heart failure patients with preserved and reduced ejection fraction. European journal of heart failure. 2011 Sep;13(9):1013-8.
28. Darmellah A, Rücker-Martin C, Feuvray D. ERM proteins mediate the effects of Na+/H+ exchanger (NHE1) activation in cardiac myocytes. Cardiovascular research. 2009 Feb 1;81(2):294-300.
29. Alvarez BV, Villa-Abrille MC. Mitochondrial NHE1: a newly identified target to prevent heart

disease. Frontiers in Physiology. 2013 Jun 28;4:152.

30. Du Y, Zhu H, Li D, Wang L, Zhang L, Luo Y, Pan D, Huang M. Lentiviral-mediated overexpression of Akt1 reduces anoxia–reoxygenation injury in cardiomyocytes. Cell Biology International. 2014 Apr;38(4):488-96.
31. Zhavoronkov A, Vanhaelen Q, Oprea TI. Will artificial intelligence for drug discovery impact clinical pharmacology?. Clinical Pharmacology & Therapeutics. 2020 Apr;107(4):780-5.
32. Kumar M, Nguyen TN, Kaur J, Singh TG, Soni D, Singh R, Kumar P. Opportunities and challenges in application of artificial intelligence in pharmacology. Pharmacological Reports. 2023 Feb;75(1):3-18.
33. Van der Lee M, Swen JJ. Artificial intelligence in pharmacology research and practice. Clinical and Translational Science. 2023 Jan;16(1):31-6.
34. Van Laar SA, Gombert-Handoko KB, Guchelaar HJ, Zwaveling J. An electronic health record text mining tool to collect real-world drug treatment outcomes: a validation study in patients with metastatic renal cell carcinoma. Clinical Pharmacology & Therapeutics. 2020 Sep;108(3):644-52.
35. Noorbakhsh-Sabet N, Zand R, Zhang Y, Abedi V. Artificial intelligence transforms the future of health care. The American journal of medicine. 2019 Jul 1;132(7):795-801.
36. Mak KK, Balijepalli MK, Pichika MR. Success stories of AI in drug discovery-where do things stand?. Expert opinion on drug discovery. 2022 Jan 2;17(1):79-92.
37. Chaturvedula A, Calad-Thomson S, Liu C, Sale M, Gattu N, Goyal N. Artificial intelligence and pharmacometrics: time to embrace, capitalize, and advance?. CPT: pharmacometrics & systems pharmacology. 2019 Jul;8(7):440.
38. Kumar M, Nguyen TN, Kaur J, Singh TG, Soni D, Singh R, Kumar P. Opportunities and challenges in application of artificial intelligence in pharmacology. Pharmacological Reports. 2023 Feb;75(1):3-18.
39. Jabeen A, Ranganathan S. Applications of machine learning in GPCR bioactive ligand discovery. Current opinion in structural biology. 2019 Apr 1;55:66-76.
40. Bertucci F, Le Corroller-Soriano AG, Monneur A, Fluzin S, Viens P, Maraninchi D, Gonçalves A. Santé numérique et «cancer hors les murs», Big Data et intelligence artificielle. Bulletin du cancer. 2020 Jan 1;107(1):102-12.
41. Seyhan AA, Carini C. Are innovation and new technologies in precision medicine paving a new era in patients centric care?. Journal of translational medicine. 2019 Dec;17:1-28.
42. Alhussein M, Muhammad G, Hossain MS. EEG pathology detection based on deep learning. IEEE Access. 2019 Feb 24;7:27781-8.
43. Jain R, Sontisirikit S, Iamsirithaworn S, Prendinger H. Prediction of dengue outbreaks based on disease surveillance, meteorological and socio-economic data. BMC infectious diseases. 2019 Dec;19(1):1-6.
44. Aronson JK. A manifesto for clinical pharmacology from principles to practice. British journal of clinical pharmacology. 2010 Jul;70(1):3.
45. Santos R, Ursu O, Gaulton A, Bento AP, Donadi RS, Bologa CG, Karlsson A, Al-Lazikani B, Hersey A, Oprea TI, Overington JP. A comprehensive map of molecular drug targets. Nature reviews Drug discovery. 2017 Jan;16(1):19-34.
46. Edwards AM, Isserlin R, Bader GD, Frye SV, Willson TM, Yu FH. Too many roads not taken. Nature. 2011 Feb 10;470(7333):163-5.
47. Sun Y, Barber R, Gupta M, Aggarwal CC, Han J. Co-author relationship prediction in heterogeneous bibliographic networks. In2011 International Conference on Advances in Social Networks Analysis and Mining 2011 Jul 25 (pp. 121-128). IEEE.

48. Kumar M, Nguyen TN, Kaur J, Singh TG, Soni D, Singh R, Kumar P. Opportunities and challenges in application of artificial intelligence in pharmacology. Pharmacological Reports. 2023 Feb;75(1):3-18.
49. Gul F, Mir I, Rahiman W, Islam TU. Novel implementation of multi-robot space exploration utilizing coordinated multi-robot exploration and frequency modified whale optimization algorithm. IEEE Access. 2021 Feb 1;9:22774-87.
50. Kumar M, Nguyen TN, Kaur J, Singh TG, Soni D, Singh R, Kumar P. Opportunities and challenges in application of artificial intelligence in pharmacology. Pharmacological Reports. 2023 Feb;75(1):3-18.
51. Jaiswal P, Mandal M, Mishra A. Effect of hesperidin on fluoride-induced neurobehavioral and biochemical changes in rats. Journal of Biochemical and Molecular Toxicology. 2020 Nov;34(11):e22575.
52. Ghosh S, Singh A. The scope of Artificial Intelligence in mankind: A detailed review. InJournal of Physics: Conference Series 2020 May 1 (Vol. 1531, No. 1, p. 012045). IOP Publishing.
53. Van der Lee M, Allard WG, Bollen S, Santen GW, Ruivenkamp CA, Hoffer MJ, Kriek M, Guchelaar HJ, Anvar SY, Swen JJ. Repurposing of diagnostic whole exome sequencing data of 1,583 individuals for clinical pharmacogenetics. Clinical Pharmacology & Therapeutics. 2020 Mar;107(3):617-27.
54. Sharma S, Shukla A, Tiwari R. Multi robot area exploration using nature inspired algorithm. Biologically Inspired Cognitive Architectures. 2016 Oct 1;18:80-94.